News

Dear Customers and Partners

As we know, the whole world is experiencing an unprecedented challenge at this time. First and foremost, we are totally committed to doing our best to support the interests and safety of our volunteers, customers, partners and employees – indeed all stakeholders.

Charité – Universitätsmedizin Berlin itself is a leading centre of expertise in CoronaVirus. As such, Charité Research Organisation – in conjunction with Charité – is actively pursuing clinical studies in relation to SARS-CoV-2. We encourage sponsors to contact us in relation to such projects.

However, at this time, we have determined that it is prudent to halt all other study recruitment, consenting and screening activities - asides from studies directly related to CoronaVirus which will be actively pursued.

Furthermore, individual studies are being put on temporary hold in accordance with sponsor instructions and good practice. In particular, this applies to studies with potentially immunosuppressive agents. However, such actions are also being taken due to logistics challenges that are facing businesses worldwide.

Other studies are continuing with the subjects currently enrolled, as far as is logistically possible.

We are remaining in ongoing contact with all sponsors and stakeholders. We have in place a robust and regularly updated continuity and mitigation plan. The actions outlined above are in accordance with current best advice and our graduated plan.

It is our aim and intention to resume operations in an orderly fashion when most prudent to do so.

At this time, we are continuing with submission and set-up work for studies with this intent in mind.  

 By working together we will overcome the challenges we all face and move forward together.

Prof. Dr. med. Frank Wagner

CEO & Chief Scientific Officer